Vera Therapeutics (VERA) Consolidated Net Income (2020 - 2026)
Vera Therapeutics (VERA) posted Consolidated Net Income of -$288.2 million for Q1 2026, down 206.24% on a QoQ basis from -$94.1 million in Q4 2025, and down 365.36% year-over-year from $108.6 million in Q1 2025.
Vera Therapeutics (VERA) Consolidated Net Income (2020 - 2026) Analysis & Trends
Vera Therapeutics' Consolidated Net Income history runs 7 years deep, the most recent figure standing at -$288.2 million for Q1 2026.
- Quarterly Consolidated Net Income fell 365.36% year-over-year to -$288.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$556.3 million (down 165.96% YoY) and the FY2025 annual result came in at $62.9 million, up 6292000.0% from the prior year.
- Consolidated Net Income was -$288.2 million for Q1 2026 at Vera Therapeutics, down from -$94.1 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$17.7 million in Q1 2022 and bottomed at -$288.2 million in Q1 2026.
- A 5-year average of -$60.1 million and a median of -$39.1 million in 2023 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2023 — Consolidated Net Income rose 24.19% — and 2026, when it tumbled 365.36%.
- Vera Therapeutics' Consolidated Net Income stood at -$33.2 million in 2022, then declined by 17.67% to -$39.1 million in 2023, then dropped by 28.21% to -$50.1 million in 2024, then sank by 87.99% to -$94.1 million in 2025, then slumped by 206.24% to -$288.2 million in 2026.
- Business Quant data shows VERA's Consolidated Net Income at -$288.2 million in Q1 2026, -$94.1 million in Q4 2025, and -$81.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Vera Therapeutics | 2.55 Bn | 2.55 Bn | - | -288.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -288.25 Mn |
| Dec 31, 2025 | -94.13 Mn |
| Sep 30, 2025 | -81.42 Mn |
| Jun 30, 2025 | -92.52 Mn |
| Mar 31, 2025 | -61.94 Mn |
| Dec 31, 2024 | -50.07 Mn |
| Sep 30, 2024 | -53.00 Mn |
| Jun 30, 2024 | -44.16 Mn |
| Mar 31, 2024 | -33.50 Mn |
| Dec 31, 2023 | -39.05 Mn |
| Sep 30, 2023 | -25.26 Mn |
| Jun 30, 2023 | -21.01 Mn |
| Mar 31, 2023 | -30.51 Mn |
| Dec 31, 2022 | -33.19 Mn |
| Sep 30, 2022 | -33.32 Mn |
| Jun 30, 2022 | -23.44 Mn |
| Mar 31, 2022 | -17.65 Mn |
| Dec 31, 2021 | -16.60 Mn |
| Sep 30, 2021 | -7.25 Mn |
| Jun 30, 2021 | -5.85 Mn |